Bavarian Nordic A/S’s chief executive officer says the proposed buyout offer from two private equity firms underscores the capital needed to back the Danish biotech’s ambition of becoming a global vaccine powerhouse.
Nordic Capital and Permira share Bavarian’s vision of turning “unloved” vaccine assets into growth engines, which will demand substantial new funding, CEO Paul Chaplin said in an interview on Friday.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.